Article Text

Download PDFPDF
Anti-Müllerian Hormone Level in Older Women: Detection of Granulosa Cell Tumor Recurrence
  1. Yih Harng Chong, MbChB*,,
  2. Archibald John Campbell, MD,
  3. Stephanie Farrand, MBBS, FRACP and
  4. Ian S. McLennan, PhD*,§
  1. *Department of Anatomy, Otago School of Medical Sciences, University of Otago;
  2. Department of Medicine, Dunedin School of Medicine, University of Otago;
  3. Department of Endocrinology, Dunedin Public Hospital; and
  4. §Brain Health Research Centre, University of Otago, Dunedin, New Zealand.
  1. Address correspondence and reprint requests to Ian S. McLennan, PhD, Department of Anatomy, Otago School of Medical Sciences, University of Otago, Dunedin 9054, New Zealand. E-mail: ian.mclennan@otago.ac.nz.

Abstract

Objective To determine whether anti-Müllerian hormone (AMH) production resumes during normal late menopausal aging. Anti-Müllerian hormone has been proposed as a specific serum marker for adult granulosa cell tumors.

Materials and Methods Serum AMH from 21 elderly postmenopausal women (mean age, 77 years) and 9 young women (mean age, 22 years) were measured by ultrasensitive immunoassay.

Results Both median (0 pmol/L) and mean (0.48 pmol/L) serum AMH values for the elderly women were below the level of detection for the immunoassay kit. Three of the 21 participants had minimally detectable level of AMH (1.13–2.76 pmol/L). The cohort of young women had expected normal values of AMH as measurable by the same immunoassay kit.

Conclusions Serum AMH values were negligible for postmenopausal women older than 65 years. This extends the normative data for AMH to 108 years old, providing a reference range for the detection of granulosa cell tumors in postmenopausal women.

  • Anti-Müllerian hormone
  • Granulosa cell tumor
  • Postmenopausal women

Statistics from Altmetric.com

Footnotes

  • This work was supported by a New Economic Research Fund grant to ISM from the Ministry of Business, Innovation and Employment, New Zealand.

  • Dr Yih Harng Chong is a recipient of a Frances Cotter Scholarship from the School of Medicine, The University of Otago, New Zealand.

  • The authors declare no conflicts of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.